1. Supplementary Figure 1. Cumulative incidences of complete remission according to the treatment arm.

2. Supplementary Figure 2A
Supplementary Figure 2A. 7-year disease-free survival according to the treatment arm.
Treatment arms Patients at risk
Daunorubicin
Idarubicin
Supplementary Figure 2A. 7-year disease-free survival according to the treatment arm.

3. Supplementary Figure 2B
Supplementary Figure 2B. 7-year relapse incidence and treatment-related mortality according to the treatment arm.
Supplementary Figure 2B. 7-year relapse incidence and treatment-related mortality according to the treatment arm.

4. Supplementary Figure 3. 7-year overall survival of the patients with karyotype failures according to the treatment arm.
Treatment arms Patients at risk
Daunorubicin
Idarubicin
Supplementary Figure 3. 7-year overall survival of the patients with karyotype failures according to the treatment arm.

5. Supplementary Figure 4A
Supplementary Figure 4A. 7-year disease-free survival of the patients with favourable risk cytogenetics according to the treatment arm.
Treatment arms Patients at risk
Daunorubicin
Idarubicin
Supplementary Figure 4A. 7-year disease-free survival of the patients with favourable risk cytogenetics according to the treatment arm.

6. Supplementary Figure 4B
Supplementary Figure 4B. 7-year disease-free survival of the patients with intermediate risk cytogenetics according to the treatment arm.
Treatment arms Patients at risk
Daunorubicin
Idarubicin
Supplementary Figure 4B. 7-year disease-free survival of the patients with intermediate risk cytogenetics according to the treatment arm.

7. Supplementary Figure 4C
Supplementary Figure 4C. 7-year disease-free survival of the patients with unfavourable risk cytogenetics according to the treatment arm.
Treatment arms Patients at risk
Daunorubicin
Idarubicin
Supplementary Figure 4C. 7-year disease-free survival of the patients with unfavourable risk cytogenetics according to the treatment arm.

8. Supplementary Figure 4D
Supplementary Figure 4D. 7-year disease-free survival of the patients with karyotype failures according to the treatment arm.
Treatment arms Patients at risk
Daunorubicin
Idarubicin
Supplementary Figure 4D. 7-year disease-free survival of the patients with karyotype failures according to the treatment arm.

9. Supplementary Figure 5A
Supplementary Figure 5A. 7-year relapse incidence of the patients with favourable risk cytogenetics according to the treatment arm.
Supplementary Figure 5A. 7-year relapse incidence of the patients with favourable risk cytogenetics according to the treatment arm.

10. Supplementary Figure 5B
Supplementary Figure 5B. 7-year relapse incidence of the patients with intermediate risk cytogenetics according to the treatment arm.
Supplementary Figure 5B. 7-year relapse incidence of the patients with intermediate risk cytogenetics according to the treatment arm.

11. Supplementary Figure 5C
Supplementary Figure 5C. 7-year relapse incidence of the patients with unfavourable risk cytogenetics according to the treatment arm.
Supplementary Figure 5C. 7-year relapse incidence of the patients with unfavourable risk cytogenetics according to the treatment arm.

12. Supplementary Figure 5D
Supplementary Figure 5D. 7-year relapse incidence of the patients with karyotype failures according to the treatment arm.
Supplementary Figure 5D. 7-year relapse incidence of the patients with karyotype failures according to the treatment arm.